INVESTMENT THESIS: AbbVie is a biopharmaceutical company best known for its blockbuster drug Humira. Despite the incredible selling strength of this product, investors have shied away from this name due to Humira's lost patent protection in Europe and risk in the United States in 2023. Key to the AbbVie's future is the acquisition of Allergan, a deal that will diversify the company's revenue stream and give it exposure to Medical Aesthetics, neuroscience, and eye care, while also increase operating cash flow. Additionally, we believe key growth drugs Rinvoq and Skyrizi will help fill the gap once Humira loses exclusivity. Lastly, the company pays a high yielding dividend that we believe is supported by the balance sheet and well covered by the cash flow.